UC regents appoint Dr. Owen Witte University Professor
Dr. Owen Witte, renowned scientist and esteemed member of UCLA’s faculty, has been appointed a University Professor by the University of California Board of Regents. This appointment is reserved for scholars of the highest international distinction, who are respected as teachers of exceptional ability and whose contributions elevate the entire UC system.
The University Professor title was established by the regents so that the entire UC system can benefit from the talents of outstanding faculty. Witte joins the ranks of just 40 UC faculty, including several Nobel laureates, who have received this honor since 1960.
“Dr....
Source: UCLA Newsroom: Health Sciences - June 10, 2016 Category: Universities & Medical Training Source Type: news
CANCER BREAKTHROUGH: Scientists find drugs to target ‘Achilles heel’ of leukaemia
THE ‘Achilles heel’ of chronic myeloid leukaemia has been discovered by scientists - who have also found drugs to successfully target this weakness and eradicate the disease in mice. (Source: Daily Express - Health)
Source: Daily Express - Health - June 8, 2016 Category: Consumer Health News Source Type: news
Cancer Patients with ACA Policies Swiftly Reach Out-of-Pocket Caps
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org
ASCO Abstract #6504
FOR IMMEDIATE RELEASE on Saturday, June 4, 2016
DURHAM, N.C. – A hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act marketplace.
The findings, reported by researchers at the Duke Cancer Institute at the American Society of Clinical Oncology meeting in Chicago (Abstract #6504), found that cancer patients buying ...
Source: DukeHealth.org: Duke Health Features - June 4, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Journey of a Yale, NYU and Columbia Graduate in Understanding Bipolar II Disorder
Tochi Onyebuchi is a Columbia Law School, NYU's Tisch School of the Arts, and Yale graduate with strong experience in both domestic and international legal work and research. He has studied extensively in France, conducted research in the Balkans, and worked on a team to help secure habeas corpus relief for a man unjustly imprisoned in Connecticut. He has appeared in Nowhere Magazine, Asimov's Science Fiction, and the critically-acclaimed anthology Panverse Three.
In our conversation below, we sat down to discuss the perception and reality of bipolar II disorder, alongside mental health issues such as addiction and comorb...
Source: Healthy Living - The Huffington Post - June 3, 2016 Category: Consumer Health News Source Type: news
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Divestiture to Incyte Strengthens Financial Position
ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50%
CAMBRIDGE, Mass.--(Healthcare Sales & Mark... Biopharmaceuticals, Oncology, Licensing, AcquisitionsARIAD Pharmaceuticals, Incyte, Iclusig, ponatinib, chronic myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2016 Category: Pharmaceuticals Source Type: news
Allogeneic HSCT offers good survival for select TKI-refractory CML patients
Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests. (Source: MedWire News)
Source: MedWire News - May 18, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Real-world CML management in line with ELN guidelines
The first-line treatment and monitoring of patients with chronic phase–chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. (Source: MedWire News)
Source: MedWire News - May 18, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
EPIC Results Shed Light On First-Line Ponatinib Risk–Benefit Profile
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase–chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators. (Source: MedWire News)
Source: MedWire News - May 18, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
CML treatment-free remission criteria outlined
Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy. (Source: MedWire News)
Source: MedWire News - May 18, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Drug- Induced Pneumonitis: A Rare Complication of Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia
2012Post date: Tuesday, May 17, 2016 - 16:23Books and theses (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - May 17, 2016 Category: Respiratory Medicine Authors: GAtherton Source Type: news
BCR–ABL halving time indicates CML prognosis during front-line TKI
Calculating halving time of the BCR–ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers. (Source: MedWire News)
Source: MedWire News - April 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Bosutinib shows ‘low’ vascular, cardiac event risk profile
Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia. (Source: MedWire News)
Source: MedWire News - April 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Imatinib-related symptom burden linked to adherence in Indian CML patients
Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Frontline nilotinib supported for newly diagnosed CP–CML
Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia diagnosis. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Pre-TKI cytokine profiling predicts CP–CML outcome
Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase–chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
